CAI
GSK icon

Capital Advisors Inc’s GSK GSK Stock Holding History

Capital Advisors Inc’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-86,424
Closed -$4.38M – 139
2016
Q1 		$4.38M Sell
86,424
-38,896
-31% -$1.94M 0.72% 60
2015
Q4 		$6.32M Buy
125,320
+1,322
+1% +$67.4K 1.11% 45
2015
Q3 		$5.96M Sell
123,998
-51,480
-29% -$2.68M 1.07% 48
2015
Q2 		$9.14M Buy
175,478
+11,497
+7% +$647K 1.57% 26
2015
Q1 		$9.46M Buy
163,981
+21,598
+15% +$1.24M 1.16% 27
2014
Q4 		$7.61M Buy
142,383
+21,762
+18% +$1.22M 1.41% 34
2014
Q3 		$6.93M Buy
120,621
+21,190
+21% +$1.3M 1.42% 36
2014
Q2 		$6.65M Buy
99,431
+14,916
+18% +$1.01M 1.29% 38
2014
Q1 		$5.64M Buy
84,515
+12,716
+18% +$860K 1.23% 42
2013
Q4 		$4.79M Buy
71,799
+8,094
+13% +$525K 1.05% 48
2013
Q3 		$4M Buy
63,705
+8,352
+15% +$538K 0.96% 50
2013
Q2 		$3.46M Buy
+55,353
New +$3.51M 0.93% 50

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Capital Advisors Inc's GSK Position: Q2 2016 in Review

Capital Advisors Inc sold out of GSK (GSK) in Q2 2016, closing a stake of 86,424 shares — an estimated $4.38M sold.

Capital Advisors Inc first reported a position in GSK in Q2 2013 and held it in 12 quarters. The position peaked at $9.46M in Q1 2015. 741 funds tracked by Wall St. Rank hold GSK as of Q2 2016.

  • Capital Advisors Inc reported no remaining GSK position as of Q2 2016 after selling out during the quarter.
  • Capital Advisors Inc sold 86,424 GSK shares in Q2 2016, an estimated $4.38M.
  • Capital Advisors Inc first reported a position in GSK in Q2 2013 and held it in 12 quarters.
  • Capital Advisors Inc's GSK position peaked at $9.46M in Q1 2015.
  • 741 funds tracked by Wall St. Rank held GSK as of Q2 2016.

Based on Capital Advisors Inc's 13F filing for Q2 2016, filed 9 Aug 2016.